使用68Ga前列腺特异性膜抗原-11（HBED-CC）PET/MRI对前列腺癌生化复发的前列腺成像复发报告（PI-RR）系统进行验证：一项初步研究。

Validation of the Prostate Imaging for Recurrence Reporting (PI-RR) System using 68Ga prostate-specific membrane antigen-11 (HBED-CC) PET/MRI in biochemical recurrence of prostate cancer: a pilot study.

作者信息

Uslu-Beşli Lebriz, Turkbey Baris, Bakir Bariş, Durmaz Selahattin, Demirdağ Çetin, Sayman Haluk Burçak

机构信息

Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.

出版信息

Nucl Med Commun. 2025 Jun 20. doi: 10.1097/MNM.0000000000002016.

DOI:10.1097/MNM.0000000000002016

PMID:40539467

Abstract

OBJECTIVE

To assess the diagnostic performance of Prostate Imaging for Recurrence Reporting (PI-RR) system using 68Ga prostate-specific membrane antigen (PSMA)-11 (HBED-CC) PET/MRI in prostate cancer (PCa) patients with biochemical recurrence (BCR).

METHODS

PET/MRI data of 31 PCa patients [17 with radical prostatectomy (RP) and 14 with radiotherapy (RT)] with BCR were retrospectively analyzed. All patients underwent PSMA PET/MRI and multiparametric prostate MRI (mpMRI). Images were evaluated using PI-RR system for mpMRI and the European Association of Nuclear Medicine standardized reporting guidelines (E-PSMA) for PET, with PI-RR and E-PSMA scores dichotomized as ≤2 negative and ≥3 positive for recurrence. Diagnostic performances were assessed using expert-based ground truth establishment.

RESULTS

Sensitivity, specificity, and accuracy were 64.7%, 85.7%, and 74.2%, respectively, for PET and 70.6%, 100%, and 83.9%, respectively, for PI-RR. While PI-RR did not reveal any false positive lesions, five patients with false negative PI-RR results were also negative with PET. In patients with RP, sensitivity, specificity, and accuracy were 44.4%, 100%, and 70.6%, respectively, for PET and 55.6%, 100%, and 76.5%, respectively, for PI-RR. For patients with RT, these values were 87.5%, 66.7%, and 78.6%, respectively, for PET and 87.5%, 100%, and 92.9%, respectively, for PI-RR. There was no significant performance difference between PET or PI-RR in all patients (P = 0.564), patients with RP (P = 0.317), or RT (P = 0.157).

CONCLUSION

68Ga PSMA PET evaluation with E-PSMA and mpMRI interpretation with PI-RR have similar diagnostic performance for detection of local recurrence after RP or RT in PCa.

摘要

目的

使用68Ga前列腺特异性膜抗原（PSMA）-11（HBED-CC）PET/MRI评估前列腺癌（PCa）生化复发（BCR）患者的前列腺影像复发报告（PI-RR）系统的诊断性能。

方法

回顾性分析31例BCR的PCa患者[17例行前列腺癌根治术（RP），14例行放疗（RT）]的PET/MRI数据。所有患者均接受PSMA PET/MRI和多参数前列腺MRI（mpMRI）检查。使用PI-RR系统评估mpMRI图像，并使用欧洲核医学协会标准化报告指南（E-PSMA）评估PET图像，将PI-RR和E-PSMA评分分为≤2分为阴性、≥3分为复发阳性。使用基于专家的金标准确定法评估诊断性能。

结果

PET的敏感性、特异性和准确性分别为64.7%、85.7%和74.2%，PI-RR分别为70.6%、100%和83.9%。虽然PI-RR未发现任何假阳性病变，但5例假阴性PI-RR结果的患者PET检查也为阴性。在RP患者中，PET的敏感性、特异性和准确性分别为44.4%、100%和70.6%，PI-RR分别为55.6%、100%和76.5%。对于RT患者，PET的这些值分别为87.5%、66.7%和78.6%，PI-RR分别为87.5%、100%和92.9%。在所有患者（P = 0.564）、RP患者（P = 0.317）或RT患者（P = 0.157）中，PET或PI-RR之间的诊断性能无显著差异。